JAGX Jaguar Health EV/EBITDA Multiple

Symbol and logo of brand Jaguar Health, Inc. (JAGX)

Jaguar Health, Inc. (JAGX) specializes in developing plant-based treatments for oncology- and HIV-related diarrhea. This price chart illustrates the impact of Mytesi scaling and the expansion of insurance coverage, with the indicator standing at 0.00. The absence of competitors guarantees the issuer significant pricing power over medication costs. Stable raw material supplies from the Amazon and route optimization completely mitigate the risk of logistical disruptions.

JAGX (Jaguar Animal Health) Enterprise Value to Operating Income Before Depreciation Ratio history from 11/23/2025 to 11/15/2026

Metric breakdowns and analytics for Jaguar Health (JAGX)

- current price and projected stock value:
Basic company analysis:Jaguar Health Corp (JAGX)
Product sample of jaguar.health

The EV/EBITDA multiple compares the total enterprise value of Jaguar Health, Inc. (JAGX), including net debt, with its operating profit before depreciation and amortization. The current value of 0.00 reflects the company's ability to generate cash flow to service its obligations. Given the absolute non-cyclical nature of demand for Jaguar Health, Inc. (JAGX) maintenance therapy, the company's trend EV/EBITDA level serves as an indicator of the business's fundamental resilience to macroeconomic shocks.